Cidara Therapeutics Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
27.68 M |
Public Float |
19.06 M |
Cidara Therapeutics Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$2.66 |
Market Cap |
$43.43 M |
Shares Outstanding |
26.64 M |
Public Float |
19.54 M |
Address |
6310 Nancy Ridge Drive San Diego California 92121 United States |
Employees | - |
Website | http://www.cidara.com |
Updated | 07/08/2019 |
Cidara Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of anti-infectives for the treatment of fungal infections. Its portfolio includes CD101 IV, CD101 Topical, and Cloudbreak. The company was founded by Kevin M. |